#USA #Boston #LifeSphere #ArisGlobal #NavaX

ArisGlobal Reports Strong Global Momentum in the First Half of 2025

In the first half of 2025, ArisGlobal, a leading technology company specializing in artificial intelligence, has reported significant progress and growth. The momentum is largely attributed to the innovative advancements made with its flagship product, LifeSphere® NavaX™, which has gained traction among numerous global pharmaceutical firms. This innovative platform aims to enhance pharmacovigilance processes and streamline operations across the board throughout the life sciences sector.

Increasing Adoption of LifeSphere® NavaX™

ArisGlobal has observed that seven large pharmaceutical companies have successfully integrated LifeSphere® NavaX™ into their safety operations. This growing adoption exemplifies the escalating trust within the industry regarding AI-powered automation solutions. Noteworthy clients include:

• - A top 10 global pharmaceutical company: Recently deployed the NavaX system for its safety report intake processes, achieving substantial efficiency gains and improved data accuracy shortly after deployment.
• - Boehringer Ingelheim: Implemented NavaX to receive safety records, achieving a data accuracy rate of 90% within a few weeks and significantly reducing manual tasks.
• - Other major pharmaceutical firms: Several others have engaged NavaX to modernize their safety record intake processes, with implementations currently underway.

These examples illustrate how LifeSphere® NavaX™ is increasingly being recognized for its practical applications in pharmacovigilance, including signal detection and document generation. This level of operational efficiency has allowed organizations to minimize manual workloads, enhance processing times, and ensure compliance with regulatory standards. The industry is witnessing a shift from isolated AI trials to widespread adoption, as evidenced by improving client results.

Commitment to Responsible AI Development

In conjunction with enhancing its services and product innovation, ArisGlobal has signed the European AI Pact. This strategic move denotes a commitment to promoting ethical and transparent AI deployment across the company and the industry.

Jason Bryant, Vice President of Product Management, AI, and Data at ArisGlobal, stated, "We are witnessing a fundamental evolution where clients are now not just experimenting with AI but operationalizing it at scale. With NavaX, we provide proven, production-ready AI integrated into real workflows, empowering security and regulatory teams to work more efficient and make informed decisions faster than ever."

Expanding Client Base and Increasing Demand

Throughout the first half of 2025, ArisGlobal has experienced a surge in demand for LifeSphere solutions, highlighting the industry's need for reliable AI-powered regulatory and safety solutions. The highlights include:

• - Four new LifeSphere pharma clients: These include organizations that rank within the top 50.
• - 31% growth among existing clients: Existing LifeSphere clients have expanded their engagements with ArisGlobal, showcasing confidence in the platform and its capabilities.

The company's shared success model, introduced in April 2025, has played a significant role in this positive trend. This model ensures that clients in the pharma sector benefit directly from automation investments, effectively linking ArisGlobal’s success to that of its clients.

Steve Nuckols, Chief Customer Officer at ArisGlobal, emphasized, "The pressure on safety and regulatory teams has never been higher. They need proven enterprise-ready solutions today, not tomorrow. LifeSphere meets these needs, enabling clients to master NavaX within just three to six months, achieving measurable results from day one."

Successful Global Implementations

ArisGlobal's teams have excelled in planning, implementing, and deploying LifeSphere solutions on a global scale. In the first half of 2025, they successfully executed:

• - 27 total implementations within its safety and regulatory LifeSphere offerings, marking a 12.5% year-over-year growth.
• - 10 implementations specifically in the APAC region, representing a remarkable 233% growth over the previous year.
• - Implementations for three of the world's 20 largest pharmaceutical companies.

Raj Hattarki, the Chief Operating Officer at ArisGlobal, explained, "In the current regulatory environment, life sciences companies require partners with a deep understanding of the urgency and complexity of modern safety and regulatory systems. Our consultants combine speed with expertise, enabling precise global implementations that highlight our ability to deliver scale, quality, and value."

Continued Innovation and AI Automation

In alignment with their growth, ArisGlobal has continued to roll out tangible innovations in the first half of 2025, advancing its product suite to tackle critical challenges efficiently. LifeSphere® NavaX™ has evolved into an enterprise solution with increased adoption and added capabilities that drive measurable productivity and compliance improvements.

Some significant innovations introduced include:

• - LifeSphere® Unify: A next-generation compliance platform consolidating safety, regulation, medical affairs, and quality into a unified ecosystem, enhancing interoperability and decision support.
• - NavaX Insights: An analytical engine designed to synthesize data from various structured and unstructured sources, revealing hidden trends and actionable signals in pharmacovigilance metrics.
• - NavaX Agent for MedDRA Coding: A capability that automates coding processes to over 80% efficiency, significantly reducing manual workload while ensuring audit-ready traceability in medical coding.
• - Advanced Compliance Docs: An automation engine tailored for regulatory documentation, streamlining the creation and collaboration of complex safety documents.

These advancements reflect ArisGlobal’s commitment to delivering practical, production-ready AI use cases, with the majority of these modules implementable within just three to six months.

Strategic Leadership and Investments

In May 2025, ArisGlobal appointed Lucinda Smith as Chief Product Officer for Safety, bringing unparalleled expertise to the organization. Smith was formerly Global Safety Operations Director at Roche, which enriches ArisGlobal's leadership with insights relevant to modern pharmacovigilance challenges and how technology can provide solutions.

According to Aman Wasan, CEO of ArisGlobal, "Amidst increasing regulatory pressures, growing filing volumes, and rising cost constraints, organizations are rethinking how they operate. They are turning to automation not just as a future aspiration but as a present necessity. Our AI-driven approach and proven ability to help clients operationalize AI substantiate the strong adoption rates and talent acquisition we are witnessing at ArisGlobal."

About ArisGlobal

ArisGlobal, an innovative technology company in the life sciences sector and developer of LifeSphere®, is transforming how leading life sciences companies create breakthroughs and bring new products to market. Based in the United States, ArisGlobal possesses regional offices in Europe, India, Japan, and China. To learn more, follow ArisGlobal on LinkedIn or visit www.arisglobal.com.